Champions Oncology, Inc is a biotechnology business based in the US. Champions Oncology shares (CSBR) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in Champions Oncology
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CSBR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- CSBR shares summary
- Compare share dealing platforms
- Is CSBR stock a buy or sell?
- Stock performance over time
- Can I short CSBR shares?
- Are CSBR shares over-valued?
- Champions Oncology's financials
- How volatile are CSBR shares?
- Does Champions Oncology pay a dividend?
- Have CSBR shares ever split?
- Other common questions
Champions Oncology stock price (NASDAQ: CSBR)Use our graph to track the performance of CSBR stocks over time.
Champions Oncology shares at a glance
|Latest market close||$9.41|
|52-week range||$7.05 - $14.68|
|50-day moving average||$9.60|
|200-day moving average||$10.71|
|Wall St. target price||$15.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.02|
Buy Champions Oncology shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Champions Oncology stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Champions Oncology price performance over time
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-5.62%|
|3 months (2021-04-30)||-12.30%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
Is Champions Oncology under- or over-valued?
Valuing Champions Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Champions Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Champions Oncology's P/E ratio
Champions Oncology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 525x. In other words, Champions Oncology shares trade at around 525x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Champions Oncology's EBITDA
Champions Oncology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.6 million.
The EBITDA is a measure of a Champions Oncology's overall financial performance and is widely used to measure a its profitability.
Champions Oncology financials
|Revenue TTM||$41 million|
|Operating margin TTM||0.89%|
|Gross profit TTM||$19.6 million|
|Return on assets TTM||0.95%|
|Return on equity TTM||5.78%|
|Market capitalisation||$140.9 million|
TTM: trailing 12 months
Shorting Champions Oncology shares
There are currently 77,910 Champions Oncology shares held short by investors – that's known as Champions Oncology's "short interest". This figure is 11.1% down from 87,687 last month.
There are a few different ways that this level of interest in shorting Champions Oncology shares can be evaluated.
Champions Oncology's "short interest ratio" (SIR)
Champions Oncology's "short interest ratio" (SIR) is the quantity of Champions Oncology shares currently shorted divided by the average quantity of Champions Oncology shares traded daily (recently around 80319.587628866). Champions Oncology's SIR currently stands at 0.97. In other words for every 100,000 Champions Oncology shares traded daily on the market, roughly 970 shares are currently held short.
However Champions Oncology's short interest can also be evaluated against the total number of Champions Oncology shares, or, against the total number of tradable Champions Oncology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Champions Oncology's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Champions Oncology shares in existence, roughly 10 shares are currently held short) or 0.0132% of the tradable shares (for every 100,000 tradable Champions Oncology shares, roughly 13 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Champions Oncology.
Find out more about how you can short Champions Oncology stock.
Champions Oncology share dividends
We're not expecting Champions Oncology to pay a dividend over the next 12 months.
Have Champions Oncology's shares ever split?
Champions Oncology's shares were split on a 1:12 basis on 11 August 2015. So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Champions Oncology shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Champions Oncology shares which in turn could have impacted Champions Oncology's share price.
Champions Oncology share price volatility
Over the last 12 months, Champions Oncology's shares have ranged in value from as little as $7.05 up to $14.68. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Champions Oncology's is 1.1844. This would suggest that Champions Oncology's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Champions Oncology overview
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized Oncology Solutions (POS) that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, the company provides POS products, including TumorGraft implants and drug panels, which utilizes TumorGraft technology to test the response of a patient's tumor to multiple oncology drugs or drug combinations. It markets its products through internet, word of mouth, and sales force to patients and physicians.
Stocks similar to Champions Oncology
Champions Oncology in the news
Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development
Champions Oncology enters drug discovery and development space
Champions Oncology Reports Quarterly Revenue of $10.6 Million
Frequently asked questionsWhat percentage of Champions Oncology is owned by insiders or institutions?
Currently 25.734% of Champions Oncology shares are held by insiders and 72.887% by institutions. When does the fiscal year end for Champions Oncology?
Champions Oncology's fiscal year ends in April. Where is Champions Oncology based?
Champions Oncology's address is: One University Plaza, Hackensack, NJ, United States, 07601 What is Champions Oncology's ISIN number?
Champions Oncology's international securities identification number is: US15870P3073 What is Champions Oncology's CUSIP number?
Champions Oncology's Committee on Uniform Securities Identification Procedures number is: 158704304
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert